tiprankstipranks
Trending News
More News >
Pharmarise Holdings Corp. (JP:2796)
:2796
Japanese Market
Advertisement

Pharmarise Holdings Corp. (2796) AI Stock Analysis

Compare
0 Followers

Top Page

JP:2796

Pharmarise Holdings Corp.

(2796)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 4o)
Rating:58Neutral
Price Target:
¥520.00
▼(-0.76% Downside)
The overall stock score is primarily influenced by moderate financial performance and technical analysis. The company's strong cash flow generation is a positive factor, but challenges in profitability and high leverage weigh heavily. The technical indicators suggest some bullish momentum, but valuation concerns due to a negative P/E ratio and potential overbought conditions limit the score.

Pharmarise Holdings Corp. (2796) vs. iShares MSCI Japan ETF (EWJ)

Pharmarise Holdings Corp. Business Overview & Revenue Model

Company DescriptionPharmarise Holdings Corp. (2796) is a diversified healthcare company specializing in the development, manufacturing, and marketing of pharmaceutical products and healthcare solutions. The company operates in several sectors, including prescription medications, over-the-counter products, and biotechnology innovations. Pharmarise focuses on providing high-quality, effective treatments across various therapeutic areas, including chronic diseases, infectious diseases, and specialty care, leveraging advanced research and development capabilities to enhance patient outcomes.
How the Company Makes MoneyPharmarise Holdings Corp. generates revenue through multiple channels, primarily by selling its pharmaceutical products to healthcare providers, pharmacies, and hospitals. The company has a significant revenue stream from prescription medications, which includes both branded and generic drugs. Additionally, Pharmarise earns income from over-the-counter products that are marketed directly to consumers. The company also invests in research and development to create innovative therapies, which can lead to lucrative licensing agreements and partnerships with other biotech firms. Collaboration with healthcare institutions and participation in clinical trials further contribute to revenue through grant funding and shared research initiatives. Overall, Pharmarise's diverse product portfolio and strategic partnerships play a crucial role in sustaining and growing its earnings.

Pharmarise Holdings Corp. Financial Statement Overview

Summary
Pharmarise Holdings Corp. shows moderate revenue growth and strong cash flow generation. However, challenges in profitability, high leverage, and negative net income impact the financial performance score.
Income Statement
55
Neutral
Pharmarise Holdings Corp. has shown moderate revenue growth with a 5.2% increase in the latest year. However, the company is struggling with profitability, as indicated by a negative net income and declining EBIT margins. The gross profit margin remains stable, but the net profit margin is negative, highlighting challenges in cost management and operational efficiency.
Balance Sheet
60
Neutral
The balance sheet reflects a moderate financial position with a debt-to-equity ratio of approximately 2.08, indicating a relatively high leverage. The equity ratio is stable, suggesting a balanced asset structure. However, the negative return on equity indicates inefficiencies in generating returns from shareholders' investments.
Cash Flow
70
Positive
Cash flow analysis shows a strong free cash flow growth rate of 74.2%, indicating improved cash generation capabilities. The operating cash flow to net income ratio is positive, suggesting effective cash conversion despite negative net income. However, the free cash flow to net income ratio is below 1, indicating potential challenges in sustaining cash flow levels.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue60.37B63.51B54.47B52.03B51.61B52.32B
Gross Profit8.20B8.96B8.45B8.13B8.12B8.07B
EBITDA878.50M1.68B1.38B2.33B2.69B2.62B
Net Income-800.00M-367.00M-351.00M333.00M447.00M426.00M
Balance Sheet
Total Assets31.10B31.92B29.49B23.42B23.75B24.72B
Cash, Cash Equivalents and Short-Term Investments2.24B4.92B7.15B4.74B3.99B4.60B
Total Debt14.25B14.28B12.75B9.14B9.91B10.70B
Total Liabilities24.10B25.01B22.05B16.43B17.05B18.39B
Stockholders Equity6.95B6.87B7.36B6.88B6.61B6.22B
Cash Flow
Free Cash Flow349.50M609.00M2.10B1.98B247.00M1.39B
Operating Cash Flow427.00M1.31B2.71B2.52B713.00M1.95B
Investing Cash Flow-1.29B-4.46B-3.12B-703.00M-292.00M-1.08B
Financing Cash Flow1.95B939.00M2.77B-1.07B-1.03B-728.00M

Pharmarise Holdings Corp. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price524.00
Price Trends
50DMA
506.48
Positive
100DMA
496.55
Positive
200DMA
492.86
Positive
Market Momentum
MACD
6.46
Negative
RSI
55.85
Neutral
STOCH
35.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2796, the sentiment is Positive. The current price of 524 is above the 20-day moving average (MA) of 516.40, above the 50-day MA of 506.48, and above the 200-day MA of 492.86, indicating a bullish trend. The MACD of 6.46 indicates Negative momentum. The RSI at 55.85 is Neutral, neither overbought nor oversold. The STOCH value of 35.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2796.

Pharmarise Holdings Corp. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
¥19.24B6.668.52%1.86%3.70%37.00%
67
Neutral
¥11.14B15.297.83%1.25%4.08%51.63%
66
Neutral
¥43.69B10.1111.53%1.27%6.65%12.77%
63
Neutral
¥14.09B11.597.77%2.59%5.93%-36.11%
60
Neutral
¥20.53B-10.54-10.03%3.54%12.75%-191.21%
58
Neutral
¥6.15B2.67%15.66%56.93%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:2796
Pharmarise Holdings Corp.
520.00
-94.05
-15.32%
JP:3417
Ohki Health Care Holdings, Inc.
1,383.00
513.93
59.14%
JP:3544
SATUDORA HOLDINGS CO., LTD.
802.00
10.72
1.35%
JP:4350
Medical System Network Co., Ltd.
464.00
30.08
6.93%
JP:7679
Yakuodo Holdings Co., Ltd.
2,213.00
-237.81
-9.70%
JP:8095
Astena Holdings Co.,Ltd.
509.00
7.34
1.46%

Pharmarise Holdings Corp. Corporate Events

Pharmarise Holdings Reports Increased Sales but Faces Profit Challenges
Apr 4, 2025

Pharmarise Holdings Corporation reported a significant increase in net sales for the first nine months of the fiscal year ending May 31, 2025, with a 14.5% year-on-year growth. However, the company faced challenges with a substantial decline in operating profit and a net loss attributable to the owners, indicating potential operational difficulties. The financial results reflect a complex market environment, and the company has made changes in accounting policies and added a new company to its consolidation scope, which may impact future performance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2025